Broadcasting from EULAR 2024: TNX-102 SL Significantly Reduces Daily Pain, Improves Fibromyalgia Symptoms
Broadcasting from EULAR 2024: TNX-102 SL Significantly Reduces Daily Pain, Improves Fibromyalgia Symptoms Phase 3 data showed TNX-102 SL (sublingual cyclobenzaprine HCI; Tonmya) significantly reduced daily pain and improved broad fibromyalgia symptoms. Tonix Pharmaceuticals presented a poster of their pivotal trial, RESILIENT, at the Annual European Congress of Rheumatology (EULAR) 2024 in Vienna, Austria. The study evaluated TNX-102 SL […]
Newly reported from EULAR 2024 – Karen Costenbader, MD: Data Supports Belimumab as Treatment in Early Lupus
Newly reported from EULAR 2024 – Karen Costenbader, MD: Data Supports Belimumab as Treatment in Early Lupus In the second part of an interview with HCPLive, Karen Costenbader, MD, director of the Lupus Program at Brigham and Women’s Hospital, discusses the 2 post hoc analyses that demonstrated treatment with belimumab reduces flares and increases response rates […]
News Coverage from EULAR 2024: Benefits of Early Belimumab Intervention in SLE, with Karen Costenbader, MD
News Coverage from EULAR 2024: Benefits of Early Belimumab Intervention in SLE, with Karen Costenbader, MD In an interview with HCPLive,Karen Costenbader, MD, director of the Lupus Program at Brigham and Women’s Hospital, gives an overview of 2 analyses that demonstrated treatment with belimumab reduces flares and increases Systemic Lupus Erythematosus Responder Index 4 (SRI-4) response […]
ESC Congress Recap: High-Impact Clinical Trials, with Deepak Bhatt, MD, MPH, MBA
ESC Congress Recap: High-Impact Clinical Trials, with Deepak Bhatt, MD, MPH, MBA With 32,000 attendees from more than 170 countries, the European Society of Cardiology (ESC) Congress 2024 demonstrated how it has earned the reputation as 1 of the foremost scientific meetings in cardiology and medicine as a whole. Boasting 4,400 novel abstracts, including 112 studies simultaneously […]
Newly reported from ESC 2024 – Aficamten in the Spotlight at ESC Congress, with Ahmad Masri, MD, MS
Newly reported from ESC 2024 – Aficamten in the Spotlight at ESC Congress, with Ahmad Masri, MD, MS Obstructive hypertrophic cardiomyopathy (HCM) is a disease state that has experienced a boom in progress during recent years. Chief among these advances, in terms of improving patient outcomes, has been the cardiac myosin inhibitor class, which recently received endorsement […]
Newscasting from ESC 2024: SEQUOIA-HCM Substudy Details Effects of Aficamten on Cardiac Structure and Remodeling
Newscasting from ESC 2024: SEQUOIA-HCM Substudy Details Effects of Aficamten on Cardiac Structure and Remodeling Leading up to an expected US Food and Drug Administration submission, which Cytokinetics expressed will be filed before the close of Q3 2024, new data at the European Society of Cardiology (ESC) Congress 2024 details the effects of aficamten from the cardiac […]
ESC Congress Study Highlights Safety of Aficamten in Hypertrophic Cardiomyopathy
ESC Congress Study Highlights Safety of Aficamten in Hypertrophic Cardiomyopathy At the European Society of Cardiology (ESC) Congress 2024, the cardiology community received its deepest insights yet into the potential of aficamten in the management of hypertrophic cardiomyopathy ahead of the anticipated Q3 submission to the US Food and Drug Administration, including an integrated safety analysis […]
Broadcasting from ESC 2024 – Siddharth Patel, MD, MPH: Abelacimab Could Help Reduce Procedure-Related Bleeding
Broadcasting from ESC 2024 – Siddharth Patel, MD, MPH: Abelacimab Could Help Reduce Procedure-Related Bleeding New data from the AZALEA-TIMI 71 trial is shedding further light on the potential benefits of factor XI inhibition with abelacimab. Presented at the European Society of Cardiology (ESC) Congress 2024, the analysis focused on periprocedural and procedural-related bleeding events, with […]
From the USA: Variable Test Performance Seen With FIT for Advanced Colorectal Neoplasia
From the USA: Variable Test Performance Seen With FIT for Advanced Colorectal Neoplasia Fecal immunochemical tests (FITs) have variable sensitivity and specificity for detecting advanced colorectal neoplasia (ACN), according to a study published online Sept. 3 in the Annals of Internal Medicine. Barcey T. Levy, M.D., Ph.D., from the University of Iowa Carver College of Medicine […]
From ESC 2024 – EMPACT-MI Kidney: SGLT2 Initiation Can Preserve Kidney Function in Post-MI Population
From ESC 2024 – EMPACT-MI Kidney: SGLT2 Initiation Can Preserve Kidney Function in Post-MI Population An analysis of the EMPACT-MI study presented at the European Society of Cardiology (ESC) Congress 2024 underlines the safety of initiating SGLT2 inhibitor therapy in patients with a history of acute myocardial infarction. The analysis demonstrates use of the SGLT2 inhibitor empagliflozin […]
